IOP Reduction in Pigmentary Glaucoma Using DSLT

Recruiting now

Conditions studied: Pigmentary Dispersion Syndrome, Pigmentary Dispersion Glaucoma

In brief

This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.

Key facts

Study ID

NCT07281391

Run by

Mann Eye Institute

People needed

45

Starts

2026-03-19

Expected to finish

2027-04-01

Last updated by the study team

2026-04-09

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss.
• Treatment naive, or washed out IOP ranging from ≥18-34 mmHg
• Central corneal thickness (CCT) 480-600 µm
• Able to complete medication washout and follow-up

You may not qualify if…

• Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye
• Prior laser trabeculoplasty <3 years
• Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years
• Patients anticipating cataract surgery within the follow-up period
• History of ocular inflammation and infection
• All other secondary glaucoma including exfoliative
• Patients unable to have DSLT treatment

Where it is running

• Mann Eye Institute — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.